Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

3.750 -0.160 (-4.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tvardi Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside ↗
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
Via Benzinga
News headline image
This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.